Q-omics provides the consensus-scored DCHS2 profile across patient tissues and cancer cell-line models. DCHS2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, DCHS2 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, DCHS2 RNA expression shows 15,055 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight BLCA, KIRC, and THYM as cancer lineages where DCHS2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DCHS2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DCHS2 survival associations across molecular data types. DCHS2 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (7) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DCHS2 RNA expression–survival associations across cancer types. High DCHS2 expression shows unfavorable associations in BLCA, LIHC, UVM, KIRP and COAD, but favorable associations in KIRC. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for DCHS2 RNA expression.
This table summarizes DCHS2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for DCHS2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DCHS2 shows lower tumor expression in BLCA, READ, BRCA and COAD and higher tumor expression in KIRC and THCA. The KIRC box plot shows higher DCHS2 RNA expression in tumor versus normal tissue (log2 FC = +0.540, t-test p < 0.001).
This table shows molecular features associated with DCHS2 in patient tissues and cancer cell lines. In patient samples, DCHS2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, DCHS2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BREAST.
